Abcellera Biologics Inc
F:8QQ

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
F:8QQ
Watchlist
Price: 2.984 EUR 2.72% Market Closed
Market Cap: 877.5m EUR

Abcellera Biologics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abcellera Biologics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Abcellera Biologics Inc
NASDAQ:ABCL
Operating Income
-$314.8m
CAGR 3-Years
N/A
CAGR 5-Years
-138%
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Operating Income
-CA$39.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Operating Income
CA$125.6k
CAGR 3-Years
-4%
CAGR 5-Years
47%
CAGR 10-Years
12%
No Stocks Found

Abcellera Biologics Inc
Glance View

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

8QQ Intrinsic Value
0.604 EUR
Overvaluation 80%
Intrinsic Value
Price

See Also

What is Abcellera Biologics Inc's Operating Income?
Operating Income
-314.8m USD

Based on the financial report for Dec 31, 2024, Abcellera Biologics Inc's Operating Income amounts to -314.8m USD.

What is Abcellera Biologics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-138%

Over the last year, the Operating Income growth was -33%.

Back to Top